Buminate Injection

Human Albumin
20%
Baxter Healthcare
Pack size
Dispensing mode
Source
Agent
Retail Price

Indications

Buminate Injection is used for: Acute hypovolaemic shock, Hypoproteinaemia

Adult Dose

Intravenous Acute hypovolaemic shock Adult: Initially, 25 g of albumin, adjusted according to patient's response. may repeat q15-30min if response inadequate Not to exceed 250 g/48 hr Hypoproteinaemia Adult: Up to 2 g/kg daily. Choice of 5% vs 20%/25% depends on whether patient requires primarily volume (5%) or primarily protein/oncotic pressure (20%/25%)

Child Dose

Intravenous Acute hypovolaemic shock Child: Up to 1 g/kg, adjusted according to patient's response. Neonatal hyperbilirubinaemia Child: 1 g/kg of albumin before exchange transfusion. Neonates (<28 days old)/infants: 10-20 mL/kg IV of 5% solution 500-1000 mg/kg IV infusion Not to exceed 250 g/48 hr or 6 g/kg/day

Renal Dose

Administration

IV Administration Do not dilute 5% solution Albumin 20%/25% may be given undiluted or diluted in NS Hypoproteinemia: Infuse over 30-120 min; not to exceed 5-10 mL/min for 5% solution, 2 mL/min for 20% solution, and 2-3 mL/min for 25% solution Hypovolemic shock Initial bolus infusion as rapidly as desired As plasma volume approaches normal, infuse 5% solution up to 2-4 mL/min and 25% solution up to 1 mL/min to avoid circulatory overload

Contra Indications

Cardiac failure, severe anaemia, history of hypersensitivity, parenteral nutrition.

Precautions

Hypertension or low cardiac reserve; additional fluids for dehydrated patients. Monitor for signs of cardiac overload in injured or postoperative patients. May carry risk of viral transmission. Volume admin and rate of infusion must always be individualised according to situation and response. Pregnancy, lactation. Lactation: Endogenous albumin found in breast milk; compatible

Pregnancy-Lactation

Interactions

Albumin solution should not be mixed by protein hydrolysates or alcoholic solutions. Risk of atypical reactions to ACE inhibitors in patients undergoing therapeutic plasma exchange with albumin human replacement.

Adverse Effects

Side effects of Human Albumin : Allergic reactions, nausea, vomiting, increased salivation, fever and chills; vascular overload, haemodilution and pulmonary oedema. Potentially Fatal: Anaphylactic shock.

Mechanism of Action

Human albumin increases intravascular oncotic pressure and causes movement of fluids from interstitial into intravascular space. Human albumin solutions are available in various concentrations. Solutions containing 5% human albumin are usually used in hypovolemic patients, whereas more concentrated 25% solutions are recommended in patients in whom fluid and sodium intake must be minimised e.g. patients with hypoproteinaemia or cerebral oedema or in paediatric patients.

Note

Buminate 20% Injection manufactured by Baxter Healthcare. Its generic name is Human Albumin. Buminate is availble in Nepal. Farmaco Nepal drug index information on Buminate Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Human Albumin :